Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismVEGFR antagonists |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A phase Ia (pharmacokinetic) study of intraperitoneal MRC202 in patients with peritoneal cancer refractory to standard treatments.
100 Clinical Results associated with MRC Biotech Pty Ltd.
0 Patents (Medical) associated with MRC Biotech Pty Ltd.
100 Deals associated with MRC Biotech Pty Ltd.
100 Translational Medicine associated with MRC Biotech Pty Ltd.